Sacroiliac Joint Arthritis Clinical Trial
Official title:
Platelet-rich Plasma in the Sacroiliac Joint
This is a double-blinded study where the injecting physicians and the patients will not know which arm they are randomized to. Each participant will be followed up for 6 months following the injection, and will have in office visits at the injection and approximately 2 weeks post injection. They will be called at month 1, 3, and 6 post injection to assess for any adverse events and number of physical therapy hours or changes in medication. At time of injection, 2 weeks post, and 1, 3 and 6 months after they will be asked to answer some questionnaires on pain and function.
Sacroiliac joint (SIJ) pain is a common and significant source of chronic low back pain. It
has been broadly defined as pain located in the area of the SIJ that can be elicited by
various pain provocation tests and relieved after infiltration of the joint with local
anesthetic.
Essentially, a patients own blood is collected and spun at varying speeds until it separates
into 3 layers, one of which is the platelet-rich plasma. Platelet-rich plasma (PRP)
injections are commonly used in various conditions including chronic tendinopathy, soft
tissue injuries, and ligamentous injuries. More recently, there has been a greater interest
in examining the efficacy of PRP as a treatment for musculoskeletal conditions affecting
joints, such as osteoarthritis (OA). To the investigators' knowledge, there are currently no
reported studies evaluating the efficacy of PRP for SIJ pain. Given the previously discussed
application and evidence behind the use of PRP in the knee and hip joints, the investigators
propose that PRP can also provide a similar solution for treating SIJ pain.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05520463 -
Fluoroscopy Versus Ultrasound Guidance for Sacral Lateral Branch Radiofrequency Ablation
|
N/A | |
Recruiting |
NCT05134181 -
Ultrasound Guided Intra-sacroiliac Joint Injection: Methylprednisolone Versus Triamcinolone
|
Phase 2 |